The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials

Journal of Rheumatology

Volumn 25, Issue 1, 1998, Pages 36-43

  Ortiz, Zulma ^a,b   Shea, Beverley ^a,c   Suarez Almazor, Maria E ^a   Moher, David ^a,d   Wells, George A ^a,d   Tugwell, Peter ^a,e  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Inst Munic Rehabilitacion P   (Argentina)

^c UNIVERSITY OF OTTAWA   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Folic acid; Folinic acid; Metaanalysis; Methotrexate; Rheumatoid arthritis

Indexed keywords

FOLIC ACID; FOLINIC ACID; METHOTREXATE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; FOLIC ACID DEFICIENCY; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADULT; ANTIDOTES; ANTIMETABOLITES, ANTINEOPLASTIC; ARTHRITIS, RHEUMATOID; DRUG INTERACTIONS; FOLIC ACID; HEMATINICS; HUMANS; LEUCOVORIN; METHOTREXATE; RANDOMIZED CONTROLLED TRIALS;

EID: 0031985832     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Kremer J. The changing face of therapy for rheumatoid arthritis. Rheum Dis Clin N Am 1995;21:845-52.
2. Tracy I, Strand G, Singh K, Alarcón G. A ten years follow-up of a large methotrexate-treated cohort of rheumatoid arthritis patients. Arthritis Rheum 1992;35:S147-B182.
3. Kremer J. Long-term prospective study of rheumatoid arthritis patients receiving methotrexate therapy: Update after 13.3 years [abstract]. Arthritis Rheum 1996; 39 Suppl: S102.
4. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: A 14 year prospective evaluation of 1017 starts. J Rheumatol 1990;17:994-1002.
5. Suarez-Almazor ME, Soskolne CL, Saunders LD, Russell AS. Use of second line drugs for the treatment of rheumatoid arthritis in Edmonton, Alberta. Patterns of prescription and longterm effectiveness. J Rheumatol 1995;22:836-43.
6. Tugwell P, Bennett K, Gent M. Methotrexate in rheumatoid arthritis. Ann Intern Med 1987;107:358-66.
7. Tugwell P, Bennett K, Gent M. Methotrexate in rheumatoid arthritis. Feedback on American College of Physicians guidelines. Ann Intern Med 1989;110:581-3.
8. Williams H, Wilkens R, Samuelson C, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1985;28:721-30.
9. Weinblatt M, Coblyn J, Fox D, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22.
10. Thompson R, Watts C, Edelman J, et al. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol 1984;11:760-3.
11. Andersen P, West S, O'Dell J, et al. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 1985;103:489-96.
12. Felson D, Anderson J, Meenan R. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two meta-analyses. Arthritis Rheum 1990;33:1449-61.
13. Felson D, Anderson J, Meenan R. Use of short-term efficacy/toxicity tradeoffs select second-line drugs in rheumatoid arthritis. A meta-analysis of published clinical trials. Arthritis Rheum 1992;35:1117-25.
14. Schnabel A, Gross WI. Low-dose methotrexate in rheumatic diseases: Efficacy, side effects and risk factors for side effects. Semin Arthritis Rheum 1994;23:310-27.
15. Kremer J, Phelps C. Long-term prospective study of the use of low-dose of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum 1992;35:138-45.
16. Wallace C, Sherry D. A practical approach to avoidance of methotrexate toxicity. J Rheumatol 1995;22:1009-12.
17. Jackson R. Biological effects of folic acid antagonists with antineoplastic activity. Pharmacol Ther 1984;25:61-82.
18. Stenger A, Houtman P, Bruyn G. Does folate supplementation make sense in patients with rheumatoid arthritis treated with methotrexate? Ann Rheum Dis 1992;51:1019-20.
19. Morgan S, Baggot J, Refsum H, Ueland P. Homocysteine levels in patients with rheumatoid arthritis treated with low-dose methotrexate. Clin Pharmacol Ther 1991;50:547-56.
20. Kremer J, Galivan J, Streckfuss A, Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 1986;29:832-4.
21. Leeb B, Witzmann G, Ogris E, et al. Folic acid and cyanocobalamin levels in serum and erythrocytes during low-dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients. Clin Exp Rheumatol 1995;13:459-63.
22. Morgan S, Baggot J, Altz-Smith M. Folate status of rheumatoid arthritis patients receiving long-term, low-dose methotrexate therapy. Arthritis Rheum 1987;30:1348-56.
23. Hine R, Alarcón G, Koopman W, et al. Serum folates levels of rheumatoid arthritis patients treated with methotrexate or other disease-modifying antirheumatic drugs [abstract]. Arthritis Rheum 1990;33 Suppl:S60.
24. Stewart K, Mackenzie A, Clough J, Wilke W. Folate supplementation in methotrexate-treated rheumatoid arthritis patients. Semin Arthritis Rheum 1991;20:332-8.
25. Tishler M, Caspi D, Fishel B, Yaron M. The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis Rheum 1988;31:906-8.
26. Morgan S, Baggot J, Vaughn W, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990;33:9-18.
27. Morgan S, Baggott J, Vaughn W, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med 1994;121:833-41.
28. Weinblatt M, Maier A, Coblyn J. Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis. An 8 week randomized placebo controlled trial. J Rheumatol 1993;20:950-2.
29. Shiroky J, Neville C, Esdaile J, et al. Low dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1993;36:795-803.
30. Joyce D, Will R, Hoffman D, et al. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis 1991;50:913-4.
31. Buckley L, Vacek P, Cooper S. Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol 1990;17:1158-61.
32. Hanrahan P, Russell A. Concurrent use of folinic acid and methotrexate in rheumatoid arthritis. J Rheumatol 1988;15:1078-80.
33. Cochrane Collaboration. The Cochrane Collaboration Handbook. Sackett DL, Oxman AD, editors. Oxford: Cochrane Collaboration, UK, 1995.
34. Arnett F, Edworthy S, Bloch D, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
35. Goldsmith CH, Boers M, Bombardier C, Tugwell P, OMERACT Committee. Criteria for clinically important changes in outcomes: Development scoring and evaluation of rheumatoid arthritis patient and trial profiles. J Rheumatol 1993;20:561-5.
36. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40.
37. Moher D, Jadad A, Nichol G, Penman M, Tugwell P, Walsh S. Assessing the quality of randomized controlled trials: An annotated bibliography of scales and checklists. Control Clin Trials 1995;16:62-73.
38. Jadad A, Moore A, Carrol D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12.
39. Landis R, Koch G. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
40. Petitti D. Meta-analysis, decision analysis, and cost-effectiveness analysis: Methods for quantitative synthesis in medicine. New York: Oxford University Press, 1994:90-114.
41. The Canadian Leucovorin Study Group. Low-dose methotrexate with leucovorin rescue in the management of rheumatoid arthritis [abstract]. J Rheumatol 1992;19 Suppl 32:39.
42. Weinblatt M, Maier A, Coblyn J. Low dose leucovorin plus methotrexate (MTX) in rheumatoid arthritis (RA): An eight week placebo controlled randomized trial [abstract]. Arthritis Rheum 1992;35 Suppl:S340.
43. Morgan S, Baggott J, Vaughn W, et al. 5 mg or 50 mg/week of folic acid supplementation does not alter the efficacy of methotrexate treated rheumatoid arthritis patients [abstract]. Arthritis Rheum 1992;35 Suppl:S343.
44. Canadian Pharmaceuticals Association. Compendium of pharmaceuticals and specialties, 31st ed: Ottawa: Canadian Pharmaceuticals Association, 1996:1267-8.
45. Detsky A, Naylor D, O'Rourke K, McGeer A, L'Abbé K. Incorporating variations in the quality of individual randomized trials into meta-analysis. J Clin Epidemiol 1992;45:255-65.
46. Moher D, Jadad A, Tugwell P. Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care 1996;12:195-208.
47. Schulz K, Chalmers I, Hayes R, Altman D. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
48. Dijkmans B. Folate supplementation and methotrexate. Br J Rheumatol 1995;34:1172-4.
49. Borigini M, Paulus H. Rheumatoid arthritis. In: Weisman M, Weinblatt M, editors. Treatment of the rheumatic diseases. Companion to the textbook of rheumatology, 1st ed. Philadelphia: WB Saunders, 1995:31-51.
50. Furst D, Clements P. Pharmacological approaches. SAARD - II. In: Klippel JH, Dieppe PA, editors. Rheumatology. St. Louis: C.V. Mosby, 1994:Ch. 8, sec 13:1-8.
51. Weinblatt M. Methotrexate. In: Kelley W, Harris E Jr, Ruddy S, Sledge C, editors. Textbook of Rheumatology, 5th ed. Philadelphia: WB Saunders, 1993:771-86.
52. Morgan S, Alarcón G, Krumdieck C. Folic acid supplementation during methotrexate therapy: It makes sense. J Rheumatol 1993;20:929-30.
53. Shiroky J. Folic acid and methotrexate in rheumatoid arthritis. Ann Intern Med 1996;124:73-4.
54. Drummond M, Bosi-Ferraz M, Mason J. Assessing the cost effectiveness of NSAID: An international perspective. J Rheumatol 1995;22:1408-14.
55. Shiroky J, Neville C. Leucovorin for methotrexate induced elevations in liver transaminases [abstract]. Arthritis Rheum 1990;33 Suppl:R34.
56. Brooks P, Day R. Toxicity of antirheumatic drugs. J Rheumatol 1995;22:998-0.
57. Cranney A, Tugwell P, Shea B, Wells G. Implications of OMERACT outcomes in arthritis and osteoporosis for Cochrane metaanalysis. J Rheumatol 1997;24:1206-7.
58. Begg C, Cho C, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996;276:637-9.